Article
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, retatrutide, which delivered weight-loss results on par with those of bariatric surgery.
In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved meaningful weight loss across all tested doses after 80 weeks:
12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight.
9 mg dose: average weight loss of 64.4 pounds, or 25.9%.
4 mg dose: average weight loss of 47.2 pounds, or 19%
Ahead of the results,...
aboutLiberty Portal
Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Mar 28, 2026 / Tyler Durden
Maersk Slaps Emergency Fuel Surcharge As War Upends Marine Supply Chains
Maersk Slaps Emergency Fuel Surcharge As War Upends Marine Supply Chains
Submitted by Michael Kern of OilPrice.com,
The war in the Middle East has upended shipping fuel markets with prices of marine fuels skyrocketing and regions running low on supply, pushing some traders to forgo cargo and ship additional fuel volumes to key bunkering ports outside the Middle East.
The price of fuel oil has surged this month as the stalled tanker traffic at the Strait of Hormuz is tightening supplies of the fuel in Asia, the key bunkering hub for fuel...
Read more
Apr 6, 2026 / Tyler Durden
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Authored by Ben Sellers via Headline USA,
Two of the major pharmaceutical companies connected with the controversial COVID vaccines were forced to abandon a new research study after failing to garner enough participants.
Pfizer and German vax maker BioNTech had sought to research an updated version of the vaccine in adults ages 50 to 64, but were unable to generate the data needed due to the low enrollment in the trials, Reuters reported.
The study was needed in order to meet new guidelines imposed by the Food and Drug Administration that...
Read more
Mar 23, 2026 / Tyler Durden
Nuclear Fuel Supply Chain Advancing Rapidly As Leading Reactor Developer X-energy Files For IPO




